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Abstract
Insulin resistance is a feature of type 2 diabetes. Resistin, secreted from adipocytes, causes insulin resistance in mice. We
previously reported that the G/G genotype of single nucleotide polymorphism (SNP) at 2420 (rs1862513) in the human
resistin gene (RETN) increased susceptibility to type 2 diabetes by enhancing its promoter activity. Plasma resistin was
highest in Japanese subjects with G/G genotype, followed by C/G, and C/C. In this study, we cross-sectionally analyzed
plasma resistin and SNPs in the RETN region in 2,019 community-dwelling Japanese subjects. Plasma resistin was associated
with SNP-638 (rs34861192), SNP-537 (rs34124816), SNP-420, SNP-358 (rs3219175), SNP+299 (rs3745367), and SNP+1263
(rs3745369) (P,10
213 in all cases). SNP-638, SNP -420, SNP-358, and SNP+157 were in the same linkage disequilibrium (LD)
block. SNP-358 and SNP-638 were nearly in complete LD (r
2=0.98), and were tightly correlated with SNP-420 (r
2=0.50, and
0.51, respectively). The correlation between either SNP-358 (or SNP-638) or SNP-420 and plasma resistin appeared to be
strong (risk alleles for high plasma resistin; A at SNP-358, r
2=0.5224, P=4.94610
2324; G at SNP-420, r
2=0.2616,
P=1.71610
2133). In haplotypes determined by SNP-420 and SNP-358, the estimated frequencies for C-G, G-A, and G-G were
0.6700, 0.2005, and 0.1284, respectively, and C-A was rare (0.0011), suggesting that subjects with A at 2358, generally had G
at 2420. This G-A haplotype conferred the highest plasma resistin (8.24 ng/ml difference/allele compared to C-G,
P,0.0001). In THP-1 cells, the RETN promoter with the G-A haplotype showed the highest activity. Nuclear proteins
specifically recognized one base difference at SNP-358, but not at SNP-638. Therefore, A at -358 is required for G at 2420 to
confer the highest plasma resistin in the general Japanese population. In Caucasians, the association between SNP-420 and
plasma resistin is not strong, and A at 2358 may not exist, suggesting that SNP-358 could explain this ethnic difference.
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Introduction
In mice, resistin is secreted from adipocytes, which antagonizes
the action of insulin both in vitro and in vivo [1,2]. While serum
resistin levels are increased in obese diabetic mice, peroxisome
proliferator–activated receptor c (PPARc) ligands reduce serum
resistin [2]. Mice that overexpress the resistin gene (retn) in the liver
are insulin-resistant through increased levels of serum resistin [3],
while mice without retn show decreased fasting plasma glucose
levels [4]. Therefore, elevated levels of serum resistin appear to be
directly related to insulin resistance in mice. In humans, resistin
appears to be mainly expressed in monocytes and macrophages
[5,6,7].
Type 2 diabetes mellitus (T2DM) is characterized by insulin
resistance in insulin target tissues, and impaired insulin secretion
from pancreatic b cells [8]. It has been reported that some single
nucleotide polymorphisms (SNPs), such as PPARc Pro12Ala,
KCNJ11 E23K, and TCF7L2 are associated with T2DM [9].
Recent genome-wide association studies (GWAS) have success-
fully identified ,20 T2DM susceptibility SNPs, but the
functional SNPs responsible for disease risk remain to be
elucidated [10].
PLoS ONE | www.plosone.org 1 March 2010 | Volume 5 | Issue 3 | e9718We previously carried out systematic analyses of SNPs in the
human resistin gene (RETN), and found that the G/G genotype of
a promoter SNP at 2420 (rs1862513) was associated with T2DM
susceptibility [11,12]. Functionally, Sp1/3 transcription factors
specifically recognized G at 2420, resulting in enhanced RETN
promoter activity. In the general Japanese population, subjects
with the G/G genotype had the highest plasma resistin levels,
followed by C/G and C/C [13]. However, the specific cis-acting
SNPs that are responsible for determining circulating resistin levels
around RETN, remains to be elucidated.
Melzer et al. reported that a SNP rs2431866, located at a distance of
,100 Kb from RETN, is associated with circulating resistin in a
genome-wide protein QTL (quantitative trait locus) analysis [14]. In an
analysis of human lymphocyte samples from 1,240 adults, Tejero et al.
reported that a QTL that influences RETN mRNA is localized on
chromosome 19p, where the strongest positional candidate is RETN
itself [15]. In a previous study, we reported that monocyte RETN
mRNA was positively correlated with its simultaneous serum level [16].
To our knowledge, no cis-acting SNPs have been shown to have
stronger effects on their relevant gene products than SNP-420.
Therefore, circulating resistin, as a model of protein QTL, merits
further investigation, and SNPs in the vicinity of RETN would be of
special interest.
In view of this, to determine the SNPs responsible for circulating
resistin around RETN, we cross-sectionally analyzed 2,019
Japanese subjects. Plasma resistin was found to be most strongly
associated with SNP-358 and SNP-420, where the relevant allele,
A at-358, was tightly linked to G at 2420.
Results
SNP-358, and SNP-638 were in nearly complete linkage
disequilibrium (LD), and were tightly correlated with
SNP-420 in the general Japanese population
We first typed the 8 SNPs listed in Table 1. All of these SNPs were
considered to be in Hardy-Weinberg equilibrium because P=0.049 for
SNP+157, and P=0.037 for SNP+1263 did not remain significant
after Bonferroni’s correction. Based on a confidence interval analysis,
SNP-638, SNP -420, SNP-358, and SNP+157 were determined to be
in the same LD block (Fig. 1). Four major haplotypes defined by SNP-
638, SNP-420, SNP-358, and SNP+157 were found (haplotype,
frequency; G-C-G-C, 0.670; A-G-A-C, 0.200; G-G-G-C, 0.073; G-G-
G-T, 0.055). Approximately 94.5% of chromosomes can be captured
by two tag SNPs, namely, SNP-358 (or SNP-638) and SNP-420. SNP-
358 and SNP-638 were in nearly complete LD (r
2=0.98), and were
tightly correlated with SNP-420 (r
2=0.50, and 0.51, respectively).
Nuclear proteins specifically recognized a difference in
one base at SNP-358 but not at SNP-638
To determine which SNP, i.e., SNP-358 or SNP-638, is
potentially functional, we examined whether nuclear proteins
Table 1. Association between each SNP around RETN and plasma resistin in the general Japanese population.
SNP
(rs No.) Genotype n HWE Plasma resistin (ng/ml)
mean 6 SD Fr
2 P
21093A.G A/A 1705 0.310 11.566.5 0.07 7.4*10
25 0.929
(rs3760678) A/G 297 11.667.3
G/G 17 11.664.0
2638G.A G/G 1304 0.056 8.263.3 1125.489 0.5275 2.75610
2329*
(rs34861192) G/A 620 16.565.9
A/A 95 24.567.6
2537A.C A/A 1855 0.417 11.866.7 31.18 0.0300 4.63610
214*
(rs34124816) A/C 159 7.863.9
C/C 5 5.263.0
2420C.G C/C 921 0.241 8.163.2 357.13 0.2616 1.71610
2133*
(rs1862513) C/G 868 13.366.5
G/G 230 18.069.1
2358G.A G/G 1300 0.073 8.263.3 1102.52 0.5224 4.94610
2324*
(rs3219175) G/A 624 16.465.9
A/A 95 24.567.7
+157C.T C/C 1804 0.049 11.66 6.6 1.62 0.0016 0.198
(rs3219177) C/T 204 10.866.5
T/T 11 10.163.6
+299G.A G/G 796 0.359 8.563.9 214.26 0.1753 5.24610
285*
(rs3745367) G/A 928 12.466.6
A/A 295 16.568.2
+1263G.C G/G 1074 0.037 12.667.2 36.64 0.0351 2.33610
216*
(rs3745369) G/C 822 10.465.7
C/C 123 9.264.4
ANOVA is used for statistical analysis (n=2,019). HWE, Hardy-Weinberg Equilibrium. *, these P values remained significant after Bonferroni’s correction (raw P value68).
doi:10.1371/journal.pone.0009718.t001
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mobility shift assay (EMSA) (Fig. 2). Nuclear proteins were found
to bind to a labeled probe with G at SNP-358 (-358G probe)(1st
lane from the left), which was reduced by a cold competitor with G
at SNP-358, but not by that with A at SNP-358 (2nd and 3rd
lanes, respectively). This suggests that nuclear proteins specifically
recognized a difference in one base at SNP-358. Consistent with
this, no specific proteins bound to a labeled probe with A at SNP-
358 (4th to 6th lanes). Regarding SNP-638, non-specific protein
binding was found with a 2638G probe (lane 7th), which was
evenly reduced by a cold competitor with G at 2628 (8th lane)
and that with A at 2638 (9th lane). The same non-specific protein
binding was observed for a 2638A probe (10th to 12th lanes). In
addition, a computer search (MatInspector program (http://www.
genomatix.de/)) revealed the presence of transcription factor
binding sites for SNP-358 but not for SNP-638. Therefore, we
tentatively concluded that SNP-358 was a more functional SNP
than SNP-638, and used SNP-358 when necessary in this study.
Plasma resistin was associated with SNP-638, SNP-537,
SNP-420, SNP-358, SNP+299, and SNP+1263 in the
general Japanese population
We next examined the relation between plasma resistin levels
and each of the 8SNPs (Table 1). Plasma resistin levels were
associated with SNP-638 (P=2.75610
2329), SNP-537
(P=4.63610
214), SNP-420 (P=1.71610
2133), SNP-358
(P=4.94610
2324), SNP+299 (P=5.24610
285), and SNP+1263
(P=2.33610
216). These P values remained significant after
Bonferroni’s correction. A low P value and high r
2were found
for SNP-358 (or SNP-638), and SNP-420 (r
2=0.5224 (0.5275),
and 0.2616, respectively). The difference in plasma resistin levels
between each genotype appears to be highest for SNP-358 (or
SNP-638), followed by SNP-420 (,8 ng/ml for SNP-358, and
,5 ng/ml for SNP-420). These findings remained unchanged
when assessed using multiple regression analyses adjusted for age,
gender, and BMI (Table 2).
When the combination of SNP-420 and SNP-358 genotypes
was analyzed, all subjects having the A/A genotype of SNP-358
also had the G/G genotype of SNP-420, and showed the highest
plasma resistin levels (ANOVA, P,0.001, and Scheffe, P,0.001
compared to subjects with each of the other genotypes)(Table 3).
Since only 4 of the 921 subjects with the C/C genotype of SNP-
420 appeared to be heterozygotes of A at-358, and none was this
homozygote, it was not possible to conclude the existence of an
effect of A at-358, independent of G at 2420. It is noteworthy that
findings reported in two previous studies suggest that the effect of
Ga t2420 is independent of A at SNP-358 in vitro [12,17].
Therefore, the G of SNP-420 and the A of SNP-358 are both
possible primary SNPs with the potential function of determining
high plasma resistin levels around RETN in the general Japanese
population.
The G-A haplotype defined by SNP-420 and SNP-358
conferred the highest plasma resistin in the general
Japanese population
To determine which combination of these potentially functional
SNPs is most responsible for plasma resistin, we examined the
relation between plasma resistin and haplotypes defined by SNP-
420 and SNP-358 in this order (Table 4). The estimated
frequencies for C-G, G-A, and G-G were 0.6700, 0.2005, and
0.1284, respectively. Since the C-A haplotype was rare (0.0011),
subjects having A at 2358, generally had a G at 2420.
Conversely, ,60% of chromosomes having G at 2420 had A at
Figure 2. Nuclear proteins specifically recognized a difference
in one base at SNP-358 but not at SNP-638. EMSA was performed
as described in Methods. A labeled probe representing RETN promoter
sequences around SNP-358 contained G (major allele) or A (minor allele)
at SNP-358 (
32P-358G or
32P-358A, respectively), and that around SNP-
638 contained G (major allele) or A (minor allele) at SNP-638 (
32P-638G
or
32P-638A, respectively). Each probe was incubated with a nuclear
extract of THP-1 cells in the absence (2) or presence of a 200-fold molar
excess of unlabeled competitor double-stranded oligonucleotides
indicated (2358G, 2358A, 2638G, or 2638A). The arrow points to
the band that specifically bound to the probe with G at SNP-358.
doi:10.1371/journal.pone.0009718.g002
Figure 1. SNP-358, and SNP-638 were nearly in complete LD,
and were tightly correlated with SNP-420 in the general
Japanese population. The 8 SNPs around RETN were genotyped in
2,019 subjects in the general Japanese population, and LD between
each pair of these SNPs were analyzed by Haploview [28]. One LD block
consisting of SNP-638, SNP -420, SNP-358, and SNP+157 was defined by
the confidence interval analysis. Each square represents a pairwise value
of D’, with the standard gradation (black indicates LOD.=2 and D’=1;
none indicates, LOD,2 and D’=1; white indicates LOD,2 and D’ ,1,
gray indicates LOD.=2 and D’,1). The r
2 between SNP-638 and SNP-
358 was 0.98. The r
2 between SNP-420 and SNP-358 or SNP-638 was
0.50, and 0.51, respectively.
doi:10.1371/journal.pone.0009718.g001
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an 8.24 ng/ml higher plasma resistin level than a low risk
reference haplotype, C-G (P,0.0001). Although C-A was
estimated to show a 2.47 ng/ml higher plasma resistin level,
compared to C-G (P=0.2700), it was not possible to verify an
effect of A at 2358 itself, independent of G at 2420, due to its low
frequency (0.0011). The G-G haplotype, with G at 2420, but not
Aa t2358, showed an effect similar to that for C-G (20.05 ng/ml
difference, P=0.8000). Therefore, G at 2420 was not sufficient to
confer the highest plasma resistin, and A at 2358 was required in
the general Japanese population. It is difficult to determine
whether A at 2358 alone or in combination with G at 2420 is
more responsible for this effect, based on only statistical analyses of
genetic data.
The RETN promoter with the G-A haplotype defined by
SNP-420 and SNP-358 showed the highest activity in
THP-1 cells
Finally, to determine the functional relevance of haplotypes
defined by SNP-420 and SNP-358, we performed transfection
experiments using THP-1 human monocytes. The RETN
promoter activity with G at 24 2 0a n dAa t 2358 showed the
higher activity than the reference control promoter with C at
2420 and G at2358 (n=8, mean 6 SE, 1.6260.16 fold;
ANOVA , P=0.002; Scheffe, P=0.008) (Fig. 3). The promoter
activity with the other two haplotypes, namely, G-G and C-A
was not different from that with C-G. Since SNP-638 was not
included in these promoter constructs, the observed effect was
independent of A at SNP-638. Therefore, from statistical
analyses of genetic data of the general Japanese population,
and in vitro functional data, A at SNP-358 is required for G at -
420 to confer the highest plasma resistin in the general Japanese
population.
Discussion
These findings herein indicate that plasma resistin levels are
associated with SNP-638, SNP-537, SNP-420, SNP-358,
SNP+299, and SNP+1263 around RETN in the general Japanese
population. The lowest P value was observed for SNP-358 (or
SNP-638), followed by SNP-420. SNP-420, and SNP-358 were in
the same LD block, and a risk allele, A of SNP-358, was tightly
linked with a risk allele, G of SNP-420. The G-A haplotype
defined by SNP-420, and SNP-358, which included these risk
alleles, conferred the highest plasma resistin. Functionally, the
RETN promoter with this haplotype showed the highest activity in
THP-1 cells. Nuclear proteins specifically recognized a difference
in one base at SNP-358, but not at SNP-638.
Table 3. Plasma resistin in subjects with each combination of
RETN SNP-420, and SNP-358 genotypes.
SNP-420 SNP-358
G/G G/A A/A
C/C 8.163.1 (917) 10.666.3 (4) N/A (0)
C/G 8.363.8 (339) 16.665.7 (529) N/A (0)
G/G 7.963.1 (44) 16.066.8 (91) 24.567.7 (95)
Plasma resistin (mean6SD) (ng/ml) is shown for each combination of SNP-420,
and SNP-358 genotypes. The number of subjects is shown in parenthesis.
Plasma resistin was higher in subjects with SNP-420G/G and SNP-358A/A
genotypes than those with any other genotypes (ANOVA, P,0.001; Scheffe,
P,0.001 compared to each of the other genotypes). N/A, not applicable
because no subjects had this combination.
doi:10.1371/journal.pone.0009718.t003
Table 2. Multiple regression analysis involving plasma resistin (ng/ml) as a dependent variable and each SNP as an independent
variable (adjusted for age, gender, and BMI).
SNP Reference
Independent
variable
Unstandardized
regression coefficient
Standard
error
Standardized
regression coefficient P
21093A.G (rs3760678) AA A/G 0.17 0.41 0.01 0.688
G/G 0.38 1.60 0.01 0.813
2638G.A (rs34861192) GG G/A 8.31 0.22 0.58 2.19610
2240
A/A 16.43 0.47 0.53 7.66610
2207
2537A.C (rs34124816) AA A/C 24.11 0.53 20.17 1.82610
214
C/C 27.09 2,89 20.05 0.014
2420C.G (rs1862513) CC C/G 5.16 0.27 0.39 3.08610
277
G/G 9.85 0.41 0.47 1.08610
2110
2358G.A (rs3219175) GG G/A 8.25 0.22 0.58 1.80610
2236
A/A 16.40 0.48 0.53 1.55610
2204
+157C.T (rs3219177) CC C/T 0.40 2.02 0.02 0.843
T/T 1.14 1.98 0.05 0.565
+299G.A (rs3745367) GG G/A 3.93 0.29 0.30 5.05610
241
A/A 8.05 0.40 0.43 8.97610
281
+1263G.C (rs3745369) GG G/C 22.22 0.30 20.17 1.43610
213
C/C 23.57 0.61 20.13 6.05610
29
Multiple regression analyses involving plasma resistin (ng/ml) as a dependent variable and each SNP genotype, age (years), gender (male=0, female=1), and BMI as
independent variables were performed as described in Methods. For each SNP genotype, S/S was compared to N/N, and N/S was compared to N/N, respectively where
the major and minor alleles based on the allele frequency were defined by normal (N), and susceptibility (S) alleles, respectively.
doi:10.1371/journal.pone.0009718.t002
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PLoS ONE | www.plosone.org 4 March 2010 | Volume 5 | Issue 3 | e9718We found that SNP-358 was associated with plasma resistin in
the order of A/A .G/A.G/G in a large number of Japanese
subjects. Subjects having the relevant allele for high plasma
resistin, i.e. an A at2358, generally had a G at 2420. In four
independent studies, the activity of the mutant RETN promoter
including G at 2420 was higher than that of the wild type
including C at 2420 in vitro [12,17,18,19]. Of these, two studies
have suggested that the effect of G at 2420 is independent of A at
SNP-358. In a previous study, we showed that Sp1/3 enhanced
RETN promoter activity with G at 2420 and G at2358 in the
absence of SNP-638 in SL2 cells [12]. The findings reported
herein indicate that RETN promoter activity with G at 2420 and
Aa t 2358 without SNP-638 was ,60% higher than that with the
other combinations. Therefore, both the A of SNP-358 and the G
of SNP-420 appear to be required for the highest RETN promoter
activity.
During the preparation of this manuscript, Asano et al. reported
on-line that rs34861192 (SNP-638G.A) and rs3745268 (39 UTR)
are significant determinants of plasma resistin in an aged Japanese
population [20]. Whereas their SNP typing data were similar to
our results, the analysis and interpretation were different from
those reported here. Based exclusively on statistical analyses of
genetic data, they concluded that SNP-638 was a more promising
candidate than SNP-420. However, SNP-638, SNP-420, and
SNP-358 were all located in the same LD block, and all of these
three SNPs were strongly associated with circulating resistin levels.
It should be pointed out that it is difficult to identify a causal
variant from highly correlated SNPs by the exclusive use of
statistical analyses of genetic data without other information [21].
Therefore, a haplotype analysis and functional data were taken
into account in assessing promising causal variants in the present
study.
Since the A at 2358 was tightly linked with the G at2420, the
issue of whether the A of SNP-358 itself is largely responsible for
high plasma resistin levels, or whether both the A of SNP-358 and
the G of SNP-420 are required remains to be elucidated. Also, the
possible relevance of SNP-358 is suggested, since the sequences
around SNP-358 are similar to the NF-kB consensus sequences
based on the MatInspector program (http://www.genomatix.de/).
The induction of RETN expression by lipopolysaccharides is
inhibited by an NF-kB inhibitor in human macrophages [22].
Although no transcription factor binding sites were detected
around SNP-638 by this program, it should be noted that SNP-
638 had the same statistical association as SNP-358. The lack of
apparent nuclear protein binding to the DNA sequence around
SNP-638 may have resulted from inappropriate reaction condi-
tions in detecting specific binding in the present study. SNP-638,
and other SNPs including SNP+299 which show low P values
clearly merit further investigation.
We previously reported that a functional promoter SNP-420
was tightly associated with plasma resistin, its final gene product,
in Japanese subjects [12,13,16]. This association is also supported
by a study reported by Cho et al. in an analysis of Korean subjects
[18], but not that by Menzaghi et al. in an analysis of Caucasian
subjects [23]. Most recently, Hivert et al. also reported that SNP-
420 was not associated with circulating resistin in Caucasian
subjects [24]. In their meta-analysis, which included Caucasians,
Japanese, and Korean subjects, SNP-420 was found to be
associated with plasma resistin with significant heterogeneity
among the groups studied, suggesting that ethnic differences
may be a factor [24]. In fact, whereas the A allele of SNP-358,
which is tightly linked with the G allele of SNP-420, showed the
strongest association with high plasma resistin in the present study,
the A allele of SNP-358 was not found in the HapMap CEU
population (http://www.hapmap.org/index.html.en). Therefore,
SNP-358 is likely to be monophormic in Caucasians, which could
account for the ethnic differences in the association between
plasma resistin and SNP-420.
Table 4. Estimated frequency and plasma resistin in each haplotype defined by RETN SNP-420, and SNP-358 genotypes.
SNP-420 SNP-358 Estimated frequency
Difference of plasma
resistin (95% CI) (ng/ml) P
C G 0.6700 0.00 = reference –
G A 0.2005 8.24(7.89–8.59) ,0.0001
GG0 . 1 2 8 4 20.05(20.47–0.37) 0.8000
C A 0.0011 2.47 (21.89–6.83) 0.2700
Frequency and plasma resistin for each haplotype defined by RETN SNP-420 and SNP-358 genotypes were estimated by SNPstats [29]. Estimated differences of plasma
resistin compared to a reference haplotype, C-G, are shown in each haplotype.
doi:10.1371/journal.pone.0009718.t004
Figure 3. The RETN promoter with the G-A haplotype defined
by SNP-420 and SNP-358 showed the highest activity in THP-1
cells. The RETN promoter reporter including 2450/206 of RETN with
each haplotype defined by SNP-420 and SNP-358 was transiently
transfected into THP-1 human monocytes. Luciferase activity was
measured as described in Methods. Relative luciferase activities are
shown as the mean fold induction 6 SE relative to the activity of the
reference promoter reporter with the C-G haplotype. The data
represent eight independent experiments with triplicate wells for each
condition. ANOVA, P=0.002. *, Scheffe, P=0.008 compared to C-G. The
base numbers were shown where the translation initiation site was
defined as +1.
doi:10.1371/journal.pone.0009718.g003
Resistin SNP and Plasma Levels
PLoS ONE | www.plosone.org 5 March 2010 | Volume 5 | Issue 3 | e9718Most recently, in ‘‘humanized resistin mice’’, where human
resistin is specifically expressed in macrophages and endogenous
retn is disrupted, a high fat diet was found to induce insulin
resistance with inflammation of adipose tissue [25]. Although this
supports the pathophysiological relevance of human resistin in
insulin resistance, it remains controversial whether circulating
resistin is associated with insulin resistance, T2DM, or adiposity in
humans [1,13]. The discrepancy among previous reports may be
resolved by analyzing SNPs that are correlated with circulating
resistin. The lower power with a smaller numbers of subjects may
also explain this difference. The broader range of the assay used in
this study could also be a contributing factor. In addition, serum
resistin probably exists as a hexamer (major form) or trimer (a
more biologically active form) in mice [26]. The presence of
multimers in human serum has been suggested, and this may also
have affected the assay results [27].
In summary, of the potentially functional SNPs, SNP-358
appears to be most strongly associated with plasma resistin in the
general Japanese population, followed by SNP-420. Subjects
having the responsible allele for the highest plasma resistin, A at
2358, generally had G at 2420. The G-A haplotype defined by
SNP-420 and SNP-358 conferred the highest plasma resistin.
Functionally, the RETN promoter with this G-A haplotype showed
the highest activity. It is not clear why A of SNP-358 is required
for G of SNP-420 to confer the highest plasma resistin, and
whether the A of SNP-358 indeed accounts for ethnic differences
in the association between plasma resistin and SNP-420. Further
studies will be required to clarify these points.
Methods
Ethics Statement
All subjects were informed of the purpose of the study and their
written consent was obtained. The study was approved by the
ethics committee of the Ehime University Graduate School of
Medicine.
Subjects
This cross-sectional study included community-dwelling Japa-
nese subjects who were attending an annual medical check-up in a
rural town located in Ehime prefecture in Japan. We previously
analyzed resistin SNP-420 and plasma resistin levels in 2,078
subjects in this population [13]. Of these subjects, 2,019 subjects,
in whom all of the eight SNPs examined in the present study were
successfully typed, were analyzed. The baseline characteristics of
the study subjects, such as alcohol habituation, history or
symptoms of cardiovascular disease (CVD), and medication-taking
were investigated by an individual interview using a structured
questionnaire. The clinical characteristics of these subjects are
summarized in Table 5.
SNP typing
The seven SNPs were selected, based on our systemic analysis of
SNPs in RETN [11,12], and one SNP (rs3745369) in the 39
flanking region was added from HapMap (http://www.hapmap.
org/index.html.en). These SNPs included all of the 4SNPs
reported in HapMap around RETN. SNPs were typed by TaqMan
analysis using assay on demand probes and primers sets (Applied
Biosystems) except rs3760678, rs34861192, rs34124816, and
rs3219177 which were generated as assay by design. The
rs1862513 was previously typed as described [13]. Genotype call
rates were rs3760678 (99.2%), rs34861192 (99.5%), rs34124816
(98.4%), rs3219175 (99.3%), rs3219177 (99.3%), rs3745367
(99.3%), and rs3745369 (99.7%).
Measurement of plasma resistin
Fasting plasma resistin was determined using a human resistin
ELISA kit (LINCO Research Inc., St. Charles, MO), according to
the manufacturer’s protocol [12]. The assay was linear below
0.16 ng/ml. Inter- and intra-assay coefficients of variation (CVs)
were 6.9 and 1.7% (low levels), and 7.2 and 8.1% (high levels),
respectively.
Electrophoretic mobility shift assay (EMSA)
THP-1 cells were grown in RPM1 medium supplemented with 10%
fetal bovine serum at 37uCi na5 %C O 2incubator. Nuclear extracts of
THP-1 cells were prepared with NE-PER
H Nuclear and Cytoplasmic
Extraction Reagents (Thermo SCIENTIFIC). The following oligonu-
cleotides were used for EMSA as probes or competitors, sense hRE-
358A, 59-CACTGTCTGCTCAGGAGCTTCCTCTTGGCCA-39;
antisense hRE-358A, 59-GATCTGGCCAAGAGGAAGCTCCT-
GAGCAGACAGTGGTAC-39; sense hRE-358G, 59-CACTGTC-
TGCTCAGGGGCTTCCTCTTGGCCA-39; antisense hRE-358G,
59-GATCTGGCCAAGAGGAAGCCCCTGAGCAGACAGTGG-
TAC-39, sense hRE-638A, 59-CGTCACTGTAGCTTCAAACTC-
CCGGGCTCAA-39; antisense hRE-638A, 59-GATCTTGAGC-
CCGGGAGTTTGAAGCTACAGTGACGGTAC-39;s e n s eh R E -
638G, 59-CGTCACTGTAGCTTCGAACTCCCGGGCTCAA-39;
antisense hRE-638G, 59-GATCTTGAGCCCGGGAGTTCGAAG-
CTACAGTGACGGTAC-39. Complementary oligonucleotides were
annealed and labeled with
32P. A 10 mg of nuclear extract was
incubated for 30 min with a
32P-labeled oligonucleotide (0.01 pmol)
and 1 mg of poly(dAdT) in reaction buffer containing 25 mM HEPES
(pH 7.9), 0.5 mM EDTA, 0.5 mM DTT, 40 mM KCl and 4% Ficoll
(v/v). Nonidet P-40 (0.5%), and a 100-fold molar excess of the
unlabeled single-stranded sense and antisense oligonucleotides,
corresponding to each labeled probe were added to reduce nonspecific
binding. Competition experiments were performed by the addition of a
Table 5. Characteristics of the population studied (n=2,019).
Sex (male/female) 883/1136
Age (years) 62.1612.6
Body mass index (kg/m
2)2 3 . 4 63.2
Systolic blood pressure (mmHg) 138.8622.4
Diastolic blood pressure (mmHg) 81.9611.9
Total cholesterol (mg/dl) 203.4634.7
Glucose (mg/dl) 98.4621.7
Insulin (mU/ml) 6.865.0
HOMA-IR 1.661.4
Resistin (ng/ml) 11.566.6
Current smoking (%) 27.8
Current drinking (%) 57.2
History of cardio vascular diseases (%) 7.3
Medication (%)
Hypertension 25.9
Type 2 diabetes 3.4
Hyperlipidemia 5.8
Values are means6SD, or n (%). Number of subjects who measured
immunoreactive insulin was 1,958. HOMA-IR (homeostasis model assessment
insulin resistance index) was calculated as glucose (mg/dl) x insulin (mU/ml)/405.
CVD indicates cardiovascular disease, including stroke, myocardial infarction,
and angina pectoris.
doi:10.1371/journal.pone.0009718.t005
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to the reaction mixture. After the binding reaction, the mixture was
subjected to 6% PAGE in 45 mM Tris, 45 mM boric acid, 1 mM
EDTA at 100V for 2 h at 4uC. The gel was dried and exposed to a
FUJIFILM imaging plate. Signals were detected with the FUJIFILM
FLA-5100 image analyzing system.
Plasmid construction
The 59 flanking region between 2450 and 2206 of RETN was
amplified by PCR using DNA from either a subject homozygous
for a wild-type allele (2420C) or a subject homozygous for a
mutant allele (2420G). These products were inserted into pGL3
basic vector (Promega, Madison, WI) to generate pGL3(2420G)
and pGL3(2420C), both of which harbor G at the 2358 locus, as
described previously[12]. These constructs were modified by using
QuickChange II Site-Directed Mutagenesis Kit (STRATAGENE,
La Jolla, CA) to generate a point mutation at 2358 from G to A.
The primers used were 59-CTTACTGTCTGCTCAGGAGC-
TTCCTCTTGGCCCCG, and 59- CGGGGCCAAGAGGA-
AGCTCCTGAGCAGACAGTAAG. The DNA fragments be-
tween 2450 and 2206 of RETN with or without this point
mutation were subsequently cloned into a luciferase reporter
vector pGL4.11 (Promega) at the site between Kpn I and Bgl II.
The sequence of the generated four plasmids, pGL4(2420C/
2358G), pGL4(2420C/2358A), pGL4(2420G/2358G) and
pGL4(2420G/2358A), were confirmed by DNA sequencing.
All plasmids used for the transfection were prepared by use of a
Qiagen plasmid kit, followed by CsCl2 density-gradient ultracen-
trifugation as described previously [12].
Transient transfection and luciferase assay
THP-1 human monocytes purchased from Human Science
Research Resources Bank (Osaka, Japan) were grown in
RPMI1640 containing 10% FCS. One day before transfection,
THP-1 cells were plated on a 6 well plate at 4.0610
5 cells/well.
Trans IT-Jurkat Reagent (Mirus, Madison, WI) was used for
transient transfection following the manufacturer’s protocol. Each
of the pGL4(2420C/2358G), pGL4(2420C/2358A), pGL4
(2420G/2358G) and pGL4(2420G/2358A) vectors was trans-
fected into these cells along with pGL4.11 basic vector (control for
basal activity), pGL4.11 promoter vector (positive control), and
pRL-SV40 internal control vector. The THP-1 cells were then
incubated with RPMI1640 containing 10% FCS for 48 hours.
Luciferase assay were performed using the Dual-Luciferase
TM
Reporter Assay System according to the manufacturer’s protocol
(Promega).
Statistical analysis
In the human population study, values are expressed as the
mean6standard deviation. Differences in plasma resistin levels
among genotypes were assessed by analysis of variance (ANOVA).
Bonferroni’s correction was applied to Table 1 (raw P value 68).
To assess isolated effects of each SNP on plasma resistin, multiple
regression analyses involving each SNP, age (year), gender
(male=1, female=0), and BMI as independent variables, and
plasma resistin (ng/ml) as a dependent variable were performed.
In these analyses, we assume that the major and minor alleles
based on the allele frequency are normal (N), and susceptibility (S)
alleles, respectively. Each SNP genotype, N/N, N/S, and S/S,
were denoted by two dummy variables (c1, c2) =(0, 0), (1, 0), and
(0, 1), respectively. This first dummy variable estimates the
difference between N/S and N/N, and the second between S/S
and N/N. These analyses were performed using a commercially
available statistical software package (JMP ver. 7, SAS Institute,
Cary, NC). Linkage disequilibrium (LD) was assessed using the
Haploview software [28]. Frequency and plasma resistin in each
haplotype defined by SNP-420 and SNP-358 genotypes were
estimated using SNPstats [29]. ANOVA followed by Scheffe as a
post-hoc test was used where indicated. Null hypotheses were
rejected at P,0.05.
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